Major Ingredients

Each capsule contains Entrectinib INN 100 mg.

Major Functionality

•ROS1-Positive Non-Small Cell Lung Cancer: Entrectinib is indicated for the treatment of adult patients with metastatic non- small cell lung cancer (NSCLC) whose tumors are ROS1- positive. •NTRK Gene Fusion- Positive Solid Tumors: Entrectinib is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, • are metastatic or where surgical resection is likely to result in severe morbidity, and • have either progressed following treatment or have no satisfactory alternative therapy.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.